EB-613 is under clinical development by Entera Bio and currently in Phase II for Osteoporosis. According to GlobalData, Phase II drugs for Osteoporosis have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EB-613’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EB-613 overview
EB-613 (Teriparatide) is under development for the treatment of post menopausal osteoporosis and non-union fractures. It is administered through oral route in the form of tablet. The therapeutic candidate is a recombinant form of the first 34 amino acids of human parathyroid hormone (PTH 1-34). It acts by targeting parathyroid hormone receptor 1. The drug candidate is developed based on Entera's platform technology. The technology combines two components to increase drug half-life and bioavailability.
See Also:
Entera Bio overview
Entera Bio is a biopharmaceutical company that specializes in the oral delivery of molecules and biologics. The company develops novel drug delivery platforms for oral delivery of large molecule protein active pharmaceutical ingredients. It offers product candidates such as EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Its other pipeline products include GLP-2 for short bowel syndrome and hGH for GH deficiency. Entera Bio conducts clinical trials on its proprietary technology which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal tract. The company also provides treatment for bone healing. It operates in Israel and the US. Entera Bio is headquartered in Jerusalem, Israel.
For a complete picture of EB-613’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
